Drug Development

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

CMO executives share their opinions on where outsourcing is going and what is driving market change.

The Future of Contract Services

After launching a new mammalian cell platform, FUJIFILM Diosynth Biotechnologies U.S.A., has acquired fast-track vaccine manufacturing knowhow and a major presence in Texas’ emerging biocorridor with Kalon, its first acquisition.

FUJIFILM's New Biopharm Game Plan

Catalent will add potent containment for blending and granulation at its New Jersey manufacturing Center of Excellence.

Catalent Expands High-Potency Handling Capability

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Government and industry efforts to address manufacturing challenges move Ebola vaccine candidates into larger clinical trials.

Ebola Treatments Ramp Up for Clinical Trials

A draft NIOSH Current Intelligence Bulletin on recommendations for reducing worker exposure to reproductive risks of drugs is available for public comment.

CDC Publishes Information on Reducing Worker Exposure to Hazardous Drugs

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Catalent and MGC Pharma Partner for Production of Cell Lines

Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs).

Sanofi Forms Strategic Pact with Boehringer Ingelheim for Biologics Manufacture

Catalent Pharma Solutions and Sanofi-Aventis R&D have entered into a collaboration to develop Sanofi’s proprietary antibodies using Catalent’s SMARTag antibody drug conjugate (ADC) platform.

Catalent and Sanofi to Collaborate on ADC Development

Mexichem announced that it acquired the distribution and sale license for HFC-227ea/P from Du Pont.

Mexichem Acquires License for DuPont’s Medical Propellant

An FDA expert committee has recommend approval of Zarizio, the first US biosimilar application from Sandoz, setting a milestone for generic biologic drugs and setting the stage for future approvals.

Formulation and Drug Delivery